Product
ABBV-101
1 clinical trial
1 indication
Indication
Hematologic CancerClinical trial
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-06-07